Robert Dwyer Nolan
Direktor/Vorstandsmitglied bei Phico Therapeutics Ltd.
Aktive Positionen von Robert Dwyer Nolan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Phico Therapeutics Ltd.
Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Robert Dwyer Nolan
Ehemalige bekannte Positionen von Robert Dwyer Nolan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENEDRIVE PLC | Direktor/Vorstandsmitglied | 01.01.2004 | 31.12.2018 |
Independent Dir/Board Member | 20.03.2015 | 31.12.2018 | |
Epistem Ltd.
Epistem Ltd. BiotechnologyHealth Technology Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - | 01.10.2008 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.1989 | 01.01.2004 |
Cardiff Biologicals Ltd. | Vorsitzender | - | - |
Gründer | - | - | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | 15.11.2010 | - |
Cardiff Protides Ltd. | Vorsitzender | - | - |
NeuTec Pharma Ltd.
NeuTec Pharma Ltd. BiotechnologyHealth Technology NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom. | Direktor/Vorstandsmitglied | 01.10.2003 | - |
Ausbildung von Robert Dwyer Nolan
King's College London | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 10 |
Operativ
Director/Board Member | 5 |
Chairman | 2 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 6 |
Commercial Services | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GENEDRIVE PLC | Health Technology |
ASTRAZENECA PLC | Health Technology |
Private Unternehmen | 6 |
---|---|
NeuTec Pharma Ltd.
NeuTec Pharma Ltd. BiotechnologyHealth Technology NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom. | Health Technology |
Phico Therapeutics Ltd.
Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Cardiff Protides Ltd. | Commercial Services |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Cardiff Biologicals Ltd. | Commercial Services |
Epistem Ltd.
Epistem Ltd. BiotechnologyHealth Technology Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Robert Dwyer Nolan
- Erfahrung